NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
StrikesCrisisMilitaryTariffTrumpPrivateAnnounceFebruaryGovernmentTimelineWinCourtOscarMajorNewsDigestFacesElectionSignificantAdditionalIranianSupremeBillionPolicy
StrikesCrisisMilitaryTariffTrumpPrivateAnnounceFebruaryGovernmentTimelineWinCourtOscarMajorNewsDigestFacesElectionSignificantAdditionalIranianSupremeBillionPolicy
All Articles
STAT+: People with intellectual and development disabilities have higher rates of anxiety, depression
STAT News
Published about 4 hours ago

STAT+: People with intellectual and development disabilities have higher rates of anxiety, depression

STAT News · Feb 23, 2026 · Collected from RSS

Summary

And other health news from the Morning Rounds newsletter

Full Article

Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a particular interest in mental health, gender-affirming care, and LGBTQ+ patient communities. You can reach Theresa on Signal at theresagaff.97.Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. The Olympics are officially over, and while I didn’t watch much, I can’t stop thinking about Alysa Liu‘s free skate. Specifically the last minute or so, after all the big jumps are done, and she’s dancing and sliding on her knees across the ice. It’s exuberant. How drugmakers are navigating Trump’s FDA Historically, decisions made by the FDA about the drugs that Americans take have been largely shielded from political influence. “It was always the case: if it’s FDA, leave it alone,” one lobbyist recently told STAT’s Daniel Payne and Lizzy Lawrence. But under the Trump administration, the strategy is morphing, with an emphasis on “currying favor” with top administration officials, as another lobbyist put it. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe


Share this story

Read Original at STAT News

Related Articles

STAT Newsabout 2 hours ago
STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications

The FDA expects a flood of applications for a new "plausible mechanism pathway" for approval of bespoke gene-editing treatments.

STAT Newsabout 2 hours ago
STAT+: Medicare’s AI ‘modernization’ project, and the Ohio hospital antitrust battle

Would you trust AI to help you pick your Medicare plan?

STAT Newsabout 3 hours ago
Ralph Abraham, No. 2 official at CDC, abruptly steps down

The No. 2 official at the CDC has resigned, adding to the drama and chaos surrounding the agency's leadership.

STAT Newsabout 4 hours ago
STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study

And other biotech news brought to you by The Readout

STAT Newsabout 4 hours ago
STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more

Pharmaceutical companies are boosting their spending on lobbying firms with connections to the White House

STAT Newsabout 5 hours ago
STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval

Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial.